Compare Verizon Communications Inc (VZ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Verizon Communications Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Verizon Communications Inc trades at $46.95 (market cap $196.40B), while State Street SPDR S&P Biotech ETF trades at $159.53. The key difference: Verizon Communications Inc pays a 5.99% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Verizon Communications Inc nearer its low. Which is the better fit depends on your goals.
| VZ | XBI | |
|---|---|---|
Market Cap | $196.40B | — |
Volume | 22,584,735 | — |
Sector | Media | Broad Market / Factor |
52-Week High | $51.38 | $164.28 |
52-Week Low | $38.40 | $86.92 |
Enterprise Value | $383.10B | — |
Dividend Yield | 5.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Verizon (VZ) trades at $46.93, down slightly by 0.21% on the day, with a bullish technical signal from moving averages. The company shows stable fundamentals with $138.19B in 2025 revenue and consistent earnings beats in recent quarters. Recent news highlights network expansion initiatives and strategic partnerships, including a fiber deal with Alphabet. Cash flow improved significantly in 2025 with $14.86B net cash flow, though debt levels remain elevated at $121.38B long-term.
VZ presents a value opportunity with a P/E of 12.31 below sector average and strong dividend yield. Analyst consensus targets $49.69 with 36.7% buy ratings, though competition from SpaceX's Starlink and high debt pose risks. The stock's current price near support at $47 suggests limited downside if technical levels hold.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
